Here's a summary of ARG-007 ✅Cationic poly-arginine peptide ✅Multiple mechanisms of action working across multiple conditions ✅Granted patents & strong IP ✅Significant pre-clinical efficacy ✅Proven safe for healthy humans Learn more ➡️bit.ly/41GcSjG

This morning, Argenica Therapeutics is pleased to announce the final patient in its Phase 2 clinical trial of ARG-007 in acute ischaemic stroke (AIS) has been dosed. Learn more about this announcement ➡️ bit.ly/42w4qEh #ASX #AGN #ARG007 #stroke #clinicaltrial

Last week, AGN announced the final patient in its Phase 2 clinical trial of ARG-007 in acute ischaemic stroke (AIS) has been dosed. Read the full announcement here ➡️ bit.ly/42w4qEh #ASX #AGN #stroke

During a recent business trip to China, Dr Liz Dallimore, had the chance to see firsthand how rapidly the country’s stroke care is evolving—and she’s optimistic about what ARG-007 could mean for patients there. Full story: investorhub.argenica.com.au/activity-updat…

April has been an exciting month for our Stage 2 Stroke Trial. Earlier this month, we announced that the last patient in the trial was dosed. Learn more about what this announcement means for the Company➡️ bit.ly/42w4qEh #ASX #AGN #clinicaltrial #stroke #ARG007

This morning, Argenica Therapeutics is pleased to lodge the following quarterly update and attached Appendix 4C Quarterly Cashflow Report for the 9-month period ended 31 March 2025. Read the full update here ➡️ bit.ly/4jCjnfa #ASX #AGN #ARG007 #clinicaltrial

Are you interested in learning more about Argenica Therapeutics? The best way to stay across company news and updates is by signing up to our Investor Hub. If you haven't already, sign up through the link below! Join here ➡️ investorhub.argenica.com.au #ASX #AGN #ARG007 #stroke

This morning, #AGN released our latest Investor Presentation. Find the latest information, including: ✅ Ischaemic stroke trial update ✅ The opportunity for ARG-007 in other indications ✅ Investment highlights Download your copy here ➡️ bit.ly/43mU9ue

This morning, Argenica Therapeutics is pleased to announce the granting of a new US patent (patent number 12,303,550) entitled “Neuroprotective Peptides” by the United States Patent Office (USPTO). Learn more here ➡️ bit.ly/3Ftbdqu #ASX #AGN #stroke #strokeawareness

The potential of ARG-007 extends past it's main stroke indication. You can learn more about our lead drug candidate in our recent Investor Presentation. Download your copy here: bit.ly/43mU9ue #ASX #AGN #investorpresentation #stroke #HIE #TBI #ARG007

This morning, #AGN has announced it has received correspondence from the United States (US) Food and Drug Administration (FDA) that it has placed a clinical hold on the Company’s Investigational New Drug (IND) Application. Read the full announcement ➡️bit.ly/3Hx4cG5

This morning, Argenica Therapeutics is pleased to announce positive preclinical data in a large cohort ferret study assessing ARG-007 efficacy out to a 14-day duration post moderate traumatic brain injury (modTBI). Read the full announcement here ➡️ bit.ly/4lgfDR8

#AGN has announced it has been awarded funding through the highly competitive Medical Research Future Fund (MRFF) Targeted Translation Research Accelerator program for Diabetes and Cardiovascular Disease, delivered by MTPConnect Learn more➡️bit.ly/3HN0TdO

Do you want to stay up to date with what's happening at Argenica Therapeutics? Join our Investor Hub to receive ASX announcements and company updates direct to your inbox! Subscribe now ➡️ bit.ly/4nNdH4u #ASX #AGN #stroke #ARG007

$AGN Argenica Therapeutics addresses FDA clinical hold on ARG-007 🧠🇺🇸 Liz Dallimore discusses US trial roadmap, FDA bottlenecks & next steps. Argenica Therapeutics Stewart Walters- Corporate #ARG007 #StrokeTherapy #ASXAGN #Biotech #FDA #ClinicalTrials

Argenica CEO, Dr Liz Dallimore recently wrote an article, "Helping to expand the acute stroke treatment window" which has been included in the latest edition of Medical Forum Magazine for August 2025. Find the article on page 46 ➡️bit.ly/3H5zjIX #AGN #stroke #TBI #HIE

Did you know August 4th to August 10th is National Stroke Week in Australia? Stroke Foundation are sharing the message to understand the signs and you could save a life. Learn more: bit.ly/3H3oZkK #NationalStrokeWeek #FAST #StrokeAwareness #StrokeWeek #AGN #ARG007

Our latest Investor Presentation is now available to download through our Investor Hub! Grab your copy here ➡️bit.ly/3Ujky8s #ASX #AGN #BioShares2025 #Stroke #ARG007

Argenica Therapeutics would like to welcome Sharon Hanegraaf to the team! Sharon has recently been appointed as Vice President of Regulatory Affairs. Learn more in our recent ASX announcement ➡️bit.ly/45pLrfU #AGN #ARG007

Argenica has now received the full clinical hold letter from the FDA outlining the additional information needed to resolve and lift the clinical hold currently in place the Company’s investigational new drug application (IND). Learn more➡️ bit.ly/411x28n